Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people

Sahakian, Barbara J and Morein-Zamir, Sharon (2015) Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people. The Lancet Psychiatry, 2 (4). pp. 357-362. ISSN 22150366

Full text not available from this repository.
Official URL: https://doi.org/10.1016/S2215-0366(15)00004-8

Abstract

Neuropsychiatric disorders typically manifest as problems with attentional biases, aberrant learning, dysfunctional reward systems, and an absence of top-down cognitive control by the prefrontal cortex. In view of the cost of common mental health disorders, in terms of distress to the individual and family in addition to the financial cost to society and governments, new developments for treatments that address cognitive dysfunction should be a priority so that all members of society can flourish. Cognitive enhancing drugs, such as cholinesterase inhibitors and methylphenidate, are used as treatments for the cognitive symptoms of Alzheimer's disease and attention deficit hyperactivity disorder. However, these drugs and others, including modafinil, are being increasingly used by healthy people for enhancement purposes. Importantly for ethical and safety reasons, the drivers for this increasing lifestyle use of so-called smart drugs by healthy people should be considered and discussions must occur about how to ensure present and future pharmacological cognitive enhancers are used for the benefit of society.

Item Type: Journal Article
Keywords: cognitive enhancement
Depositing User: Unnamed user with email sharon.morein@anglia.ac.uk
Date Deposited: 04 Jul 2017 08:03
Last Modified: 04 Jul 2017 08:03
URI: http://arro.anglia.ac.uk/id/eprint/701924

Actions (login required)

Edit Item Edit Item